ERAS Cardiac Surgery Featured at Dedicated Session at European Association for Cardio-Thoracic Surgery in Milan Springfield, MA — October 24, 2018 — The ERAS Cardiac Surgery Society presented its recent consensus statement at the 32nd European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Milan, Italy, last week as part of an educational session. This dedicated ERAS Cardiac Surgery session was held during EACTS, the world’s largest cardiothoracic surgery focused professional conference with international speakers across all subspecialties. ERAS Cardiac Surgery is a patient safety organization with the mission to facilitate optimization of perioperative care of cardiac surgical patients through collaborative discovery, analysis, expert consensus, and dissemination of best
San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency. The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.
–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the
–Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in Postoperative Atrial Fibrillation (POAF) among patients with active clearance of chest tubes after heart surgery was published in the August edition of the Journal of Thoracic and Cardiovascular Surgery. The study is titled “Examining the impact of active clearance of chest drainage catheters
Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System. New York City, NY – August 21, 2017 — ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that positive clinical trial results were presented at the International Coronary Congress (ICC) 2017 annual meeting on August 18th, 2017 in New York City, NY. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Retained Blood and ICU Resources after Off-Pump Coronary Artery Bypass Surgery”. This data stems from a